- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01259375
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma (ARSARC-PI-0010)
March 3, 2017 updated by: University of Utah
A Phase II Study of Amrubicin Chemotherapy as First Line Treatment in Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Primary Objectives
- To evaluate the Response Rate (RR) for amrubicin in patients with metastatic or advanced sarcoma as first line therapy.
- To evaluate Progression Free Survival (PFS).
Secondary Objectives
- To assess the safety and tolerability of amrubicin in this patient population.
- To evaluate whether certain histologic subtypes of sarcoma demonstrate a differential response to amrubicin.
- To investigate quality of response with radiographic evaluation using both Response Evaluation Criteria In Solid Tumors (RECIST) and Choi criteria.
- To evaluate overall survival (OS).
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Monica, California, United States, 90403
- Santa Monica
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients (age 18 years or older)
- Pathological diagnosis of soft tissue sarcoma. Pathology materials must be submitted and reviewed.
- Patients must have unresectable locally advanced or metastatic progressive disease prior to enrollment. Disease extent must be determined by scans (CT or PET CT) within 6 weeks of enrollment.
- No prior chemotherapy for soft tissue sarcoma.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function including the following:
- Adequate bone marrow reserve: absolute neutrophil count (segmented and bands) (ANC) 1.5 x 109/L, platelet count 100 x 109/L, and hemoglobin 90 g/L,
- Hepatic: bilirubin 1.5 x the upper limit of normal (ULN), ALT and AST 3.0 x ULN,
- Renal: serum creatinine 1.5 x ULN or calculated creatinine clearance greater than 60 mL/min,
- Cardiac: Left ventricular ejection fraction (LVEF) 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA);
- All labs must be done within 2 weeks prior to enrollment.
- Negative serum pregnancy test at the time of enrollment for females of childbearing potential;
- For males and females of child-producing potential, use of effective contraceptive methods during the study;
- Ability to understand the requirements of the study and provide written informed consent.
Exclusion Criteria:
- Pregnant or nursing females
- Chest radiotherapy with curative intent to the primary disease complex less than or equal to 28 days prior to first dose; cranial radiotherapy less than or equal to 21 days prior to first dose; radiotherapy to all other areas less than or equal to 7 days prior to first dose
- Concurrent severe or uncontrolled medical disease (eg, active systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure, active viral hepatitis or chronic liver disease) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study
- Symptomatic central nervous system metastases. Patients with asymptomatic brain metastases are allowed. The patient must be stable for 2 weeks after radiotherapy; if the patient is on corticosteroids, the dose of corticosteroids must have been stable for 2 weeks prior to first dose of study treatment, or be in the process of being tapered
- Suspected, diffuse idiopathic interstitial lung disease or pulmonary fibrosis.
- Patients with known history of seropositive human immunodeficiency virus (HIV) or patients who are receiving immunosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications. HIV testing is not required for inclusion in the trial.
- Known hypersensitivity to any of the components of the i.v. formulation of amrubicin.
- Psychiatric disorder or any other personal circumstances that prevent compliance with the study protocol.
- Inability or unwillingness to comply with the study protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: All patients
All participants who received Amrubicin.
|
Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy.
Time Frame: 48 months
|
Per response evaluation criteria in solid tumors criteria (RECIST 1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR) >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
|
48 months
|
Progression Free Survival
Time Frame: six months
|
Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v 1.1) for target lesions and assessed by CT; time elapsed between treatment initiation and tumor progression or death.
In target lesions, progression is defined per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
In non-target lesions, progression is defined via RECIST v 1.1 as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
|
six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Serious Adverse Events
Time Frame: 4 months
|
4 months
|
|
Overall Survival
Time Frame: two years
|
This variable reviews the percentage of Overall Survival at 24 months and presents the percentage of participants who survived at 2 years.
|
two years
|
Quality of Response With Radiographic Evaluation Using Both Response Evaluation Criteria In Solid Tumors (RECIST) and Choi Criteria.
Time Frame: 48 months
|
Per response evaluation criteria in solid tumors criteria (RECIST 1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR) >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Exploratory CT evaluations according to Choi response criteria will be also performed and correlated with RECIST response.
|
48 months
|
Differential Response to Amurbicin Among Certain Histologic Subtypes of Sarcoma.
Time Frame: 48 months
|
Per response evaluation criteria in solid tumors criteria (RECIST 1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR) >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (ACTUAL)
February 1, 2016
Study Completion (ACTUAL)
February 1, 2016
Study Registration Dates
First Submitted
December 10, 2010
First Submitted That Met QC Criteria
December 13, 2010
First Posted (ESTIMATE)
December 14, 2010
Study Record Updates
Last Update Posted (ACTUAL)
April 17, 2017
Last Update Submitted That Met QC Criteria
March 3, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCI45197
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedSoft Tissue Sarcoma, Adult | Soft Tissue Sarcoma, ChildUnited States
Clinical Trials on Amrubicin
-
Sumitomo Pharma Co., Ltd.TerminatedSmall-cell Lung CancerJapan
-
Sumitomo Pharma Co., Ltd.Completed
-
Heather WakeleeCelgeneCompletedThymic Carcinoma | Thymoma | Thymus CancerUnited States
-
Celgene CorporationWithdrawnMetastatic Breast CancerUnited States
-
CelgeneCompleted
-
CelgeneCompletedSmall Cell Lung CancerUnited States, Netherlands, United Kingdom
-
Matthew GalskyCelgeneTerminatedBladder CancerUnited States
-
Japan Multinational Trial OrganizationCompleted
-
Taiho Oncology, Inc.Taiho Pharmaceutical Co., Ltd.TerminatedSmall Cell Lung Cancer (SCLC)Japan, Italy, Germany
-
SCRI Development Innovations, LLCCelgeneCompletedMetastatic Breast CancerUnited States